top of page

Dr. Chung Kar Kin, Albert 鍾嘉健

MBBS(HK), FHKAM(Psychiatry), FHKCPsych

Clinical Assistant Professor

Director of Education
Honorary Associate Consultant, Queen Mary Hospital
Psychiatrist In-charge for Substance Abuse Clinic Services, Hong Kong West Cluster (Queen Mary Hospital and Western Psychiatric Centre)
Vice-President, the Hong Kong Society of Biological Psychiatry
Member (Professional Colleague), Academy of Cognitive Therapy, United States of America
Member, Scientific Committee, The Hong Kong College of Psychiatrists

The HKU Scholars Hub Page address:


Dr. Albert Chung joined the department in November 2017 as a clinical assistant professor. He is also the honorary associate consultant of substance abuse clinic services in the Hong Kong West Cluster. Before joining the department, he obtained Fellowship of the Hong Kong College of Psychiatrists in 2010, and was the Associate Consultant at Queen Mary Hospital since 2011.  He was awarded as the Distinguished Young Fellow by the Hong Kong College of Psychiatrists in 2015.  He is currently the accredited trainer in both General Adult Psychiatry and Substance Misuse Psychiatry by the Hong Kong College of Psychiatrists.  His research interests reside in clinical psychopharmacology, and pharmacological and non-pharmacological interventions in substance misuse psychiatry (Substance misuse To Psychiatric disorders Program—“SToP Program").

Research Interests

  • Clinical Psychopharmacology 

  • Substance Misuse (Substance misuse To Psychiatric disorders [SToP] Program): for cannabis (SToP-C), stimulants (SToP-S), and ketamine (SToP-K)

Selected Publication List


鍾嘉健 (2022)《從渴求到成癮 — 被大腦「綁架」的生理和心理機制,以及評估和治療方法》。花千樹出版有限公司。ISBN 978-962-8484-99-7

Scientific Papers:
  1. Chung K.K.A., Tse C.Y. and LAW K.C.J., Attitudes and beliefs of medical students on cannabis in Hong Kong, Complementary Therapies in Medicine. 2022, 70, 102870.

  2. Chung AKK, Chan W, Law JK, Tse C. (2021) Ketamine abusers with SLC6A3 rs393795 genotype showed a preliminary association with psychosis and schizophrenia: A pilot case-control study. Schizophr Res 230: 24-25. []

  3. Wong MMC, Chung AKK, Yeung TMH, et al. Guidance on the clinical understanding and use of long-acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements. CNS Neurosci Ther. 2021;27(Suppl. 1):5–11.

  4. Li, G., Cheung, C., Chung, A., Cheung, B., Wong, I., Fok, M., . . . Sham, P. (2020). Evaluation of bi-directional causal association between depression and cardiovascular diseases: A Mendelian randomization study. Psychological Medicine, 1-12. doi:10.1017/S0033291720003566

  5. Michael M. C. Wong,  Albert K. K. Chung,  Timothy M. H. Yeung, et al. (2020)  Consensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong.  Internal Medicine Journal 50(Suppl. 3): 6-14 []

  6. Cheng Y, Tung C-K, Chung AKK, et al. (2019) Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross- sectional study. BMJ Open 2019;9:e027193. doi:10.1136/ bmjopen-2018-027193

  7. Chung AKK (2012) Atypical Presentation of Tardive Dyskinesia associated with Risperidone Long-acting Injection as Maintenance Treatment in Bipolar Affective Disorder: a Case Report.  Current Drug Safety 7(1): 21-23.

  8. Chung AKK and Chua SE (2011) Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis.  J Psychopharmacol 2(5): 646-666. (J Psychopharmacol Online First September 8, 2010 [doi: 10.1177/0269881110376685]) 

  9. Chung AKK and Chua SE (2010) Torsade de pointes associated with low-dose amisulpride: a case report. J Psychopharmacol 24: 433-435.   (J Psychopharmacol Online First October 28, 2008 [doi:10.1177/0269881108098385])

  10. Chung AKK and Chua SE (2007) Acute Urinary Retention Associated with SSRI (Selective Serotonin Reuptake Inhibitors) and Ziprasidone.  J Clin Psychopharmacol 27(5): 517-519.

  11. López-Muñoz F, Winston WW, Shinfuku N, Pae C, Castle DJ, Chung AKK, Sim K, Álamo C (2014) A Bibliometric Study on Second-generation Antipsychotic Drugs in the Asia–Pacific Region.  J Exp Clin Med 6(4): 111-117.

Research Grants

Substance misuse To Psychiatric Disorders Program (SToP Program)


Substance misuse To Psychiatric disorder for Cannabis—repetitive Transcranial Magnetic Stimulation for people with Cannabis Use Disorder (SToP-C—rTMS x CUD)

Project No.: BDF210065 [2-year project; 2022-2024]

Funding Source: Beat Drugs Fund Regular Funding Scheme 2021, Beat Drugs Fund Association

Substance misuse To Psychiatric disorders for Cannabis—Prospective evaluation on Cognitive function and its associated Genetic vulnerability in cannabis users (SToP-C—PeCoG)
Project No.: BDF190050 [3-year project; 2020-2023]
Funding Source: Beat Drugs Fund Regular Funding Scheme 2019, Beat Drugs Fund Association

Substance misuse To Psychosis for Stimulants (SToP-S)—An Early Assertive Pharmacotherapy Intervention Study.
Project No.: BDF180059 [2-year project; 2019-2021]
Funding Source: Beat Drugs Fund Regular Funding Scheme 2018, Beat Drugs Fund Association

A Prospective Study to Evaluate the Change in Cognitive Function in Stimulant Users
Project No.: BDF 180058 [2-year project; 2019-2021]
Funding Source: Beat Drugs Fund Regular Funding Scheme 2018, Beat Drugs Fund Association

Substance misuse To Psychiatric disorders for Cannabis (SToP-C)—An Early Assertive Pharmacotherapy Intervention Pilot Study
Funding Source: Seed Fund for Basic Research for New Staff 2018

bottom of page